GIKLY - Grifols ABvac40 vaccine for Alzheimer's shows safety/response in phase 2 interim data

Grifols (NASDAQ:GRFS) unit Araclon Biotech reported results for the first part of a phase 2 trial of its vaccine ABvac40 for Alzheimer's Disease (AD) and data on two studies of its assay ABtest-MS to identify early-stage AD. The company said ABvac40 meets the main objectives on safety and efficacy of the first part of the phase 2 study. Researchers confirmed the vaccine's safety and tolerability profile, and a strong immune response in patients with amnestic mild cognitive impairment (aMCI) or very mild Alzheimer's disease (vm-AD). The administration of six doses of ABvac40 resulted in a significant increase in the specific antibody levels, greater than those seen in a phase 1 trial (three doses). The company said the data confirms those obtained in the phase 1 study and presented in July 2016, which showed a good safety profile. The mid-stage study included a 124 patients with aMCI or very mild AD and were

For further details see:

Grifols ABvac40 vaccine for Alzheimer's shows safety/response in phase 2 interim data